Evidence map›Paper›PMID 32257769›Full record

Trial reportAnalytical cellular pathology (Amsterdam)2020

Molecular and Cellular Mechanisms Responsible for Beneficial Effects of Mesenchymal Stem Cell-Derived Product "Exo-d-MAPPS" in Attenuation of Chronic Airway Inflammation.

Carl Randall Harrell, Dragica Miloradovic, Ruxana Sadikot, Crissy Fellabaum, Bojana Simovic Markovic, Dragana Miloradovic, Aleksandar Acovic, Valentin Djonov, Nebojsa Arsenijevic, Vladislav Volarevic

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Analytical cellular pathology (Amsterdam), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Carl Randall HarrellRegenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, Florida, USA.
Dragica MiloradovicCenter for Molecular Medicine and Stem Cell Research, Department for Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.
Ruxana SadikotEmory University School of Medicine, 648 Pierce Dr. NE, Atlanta, GA, USA.
Crissy FellabaumRegenerative Processing Plant, LLC, 34176 US Highway 19 N, Palm Harbor, Florida, USA.
Bojana Simovic MarkovicCenter for Molecular Medicine and Stem Cell Research, Department for Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.ORCID https://orcid.org/0000-0002-9698-8556
Dragana MiloradovicCenter for Molecular Medicine and Stem Cell Research, Department for Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.
Aleksandar AcovicCenter for Molecular Medicine and Stem Cell Research, Department for Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.
Valentin DjonovInstitute of Anatomy, University of Bern, 2 Baltzerstrasse, Switzerland.
Nebojsa ArsenijevicCenter for Molecular Medicine and Stem Cell Research, Department for Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.
Vladislav VolarevicCenter for Molecular Medicine and Stem Cell Research, Department for Microbiology and Immunology, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, Kragujevac, Serbia.ORCID https://orcid.org/0000-0001-5948-9902
University of Kragujevac · RSEmory University · USUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs), due to their potential for differentiation into alveolar epithelial cells and their immunosuppressive characteristics, are considered a new therapeutic agent in cell-based therapy of inflammatory lung disorders, including chronic obstructive pulmonary disease (COPD). Since most of the MSC-mediated beneficent effects were the consequence of their paracrine action, herewith, we investigated the effects of a newly designed MSC-derived product "Exosome-derived Multiple Allogeneic Protein Paracrine Signaling (Exo-d-MAPPS)" in the attenuation of chronic airway inflammation by using an animal model of COPD (induced by chronic exposure to cigarette smoke (CS)) and clinical data obtained from Exo-d-MAPPS-treated COPD patients. Exo-d-MAPPS contains a high concentration of immunomodulatory factors which are capable of attenuating chronic airway inflammation, including soluble TNF receptors I and II, IL-1 receptor antagonist, and soluble receptor for advanced glycation end products. Accordingly, Exo-d-MAPPS significantly improved respiratory function, downregulated serum levels of inflammatory cytokines (TNF-

Indexed as

ExosomesAgedAnimalsCulture Media, ConditionedFemaleHumansInflammationLungMaleMesenchymal Stem CellsMiceMice, Inbred BALB CMiddle AgedPlacentaPregnancyPulmonary Disease, Chronic ObstructiveCulture Media, Conditioned

Identifiers

PMID32257769
PMCPMC7109559
OpenAlexW3011047396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.